Latest News
Characteristics Found in Novel AATD Mutation Could Help Advance Treatment
New Assay Can Measure Lower Active AAT Levels in AATD
AATD Screening During Childhood and Early Adulthood May Improve Prognosis
Newly Discovered AAT Factors Might Develop Better AATD Therapies
New Findings Shed Light on Mitochondrial Damage Caused by AATD
Clear Panel Design Criteria Can Ensure Accuracy of LCFAOD Diagnosis
Novel Conjugation Strategy Improves A1AT Efficacy
Targeting C3d Levels Could Be Therapeutic for AATD
Smoking Habits Can Influence Early Symptoms in AATD
New Research Sheds Light on Adaptive Response in AATD
AATD Carriers Who Never Smoked May Have No Association With Lung Cancer
The PEGylation of AAT Demonstrates Significant Therapeutic Potential
Latest Clinical Trials
Features
Inhaled Therapy Could Transform AATD Treatment Landscape
Israeli biopharma giant Kamada is banking that its inhaled AAT therapy will “revolutionize” the treatment of alpha-1 antitrypsin deficiency (AATD).
Israel Emerges as Global Powerhouse in Rare Disease Research
TEL AVIV, Israel — On the 6th floor of Schneider Children’s Hospital in the Tel Aviv suburb of Petah Tikva, 30 children with Alagille syndrome and 2 with lysosomal acid lipase deficiency (LAL-D) receive specialized treatment from a trio of pediatric hepatologists. Across town, at Sheba Medical Center’s Edmond and Lily Safra Children’s Hospital, pediatric…
Researchers Exploring Multiple Mechanisms of Action for Treating AATD
Faron Schonfeld, a successful investment portfolio manager from Philadelphia, Pennsylvania, had for years suffered chronic coughing and sinus infections that only seemed to get worse. He was finally referred to a pulmonologist at National Jewish Health in Denver, Colorado. That’s where he got the diagnosis: Schonfeld had alpha-1 antitrypsin deficiency (AATD, or simply alpha-1) —…
Patient Perspectives
A Portacath or PICC Line Attracts Young Alpha-1 Patients
I knew some alpha-1 antitrypsin deficiency (AATD) patients have Portacaths and now I understand why.
Nutrition’s Critical Role in My Battle With AATD
Diet definitely does affect my quality of life, and those I know with alpha-1 antitrypsin deficiency (AATD) say it seems to affect them similarly.
What I Wish Others Understood About Fatigue and AATD
The profound fatigue I experienced as a result of alpha-1 antitrypsin deficiency (AATD) caused a lot of confusion and frustration for me for a long time.
AATD Patients Face Many Risk Factors for Lung Function Decline
There are certain risks that everyone takes where their lungs are concerned. As someone who has alpha-1 antitrypsin deficiency, I have more risks than most.
Alpha-1 Clinical Insights
The Role of Next-Generation Sequencing in Diagnosing Infants With Cholestasis
We explore the role of next-generation sequencing in providing a genetic diagnosis for infants with a cholestatic disease, such as Alagille syndrome or AATD.
The Feasibility of Self-Administering AAT Therapy During the COVID-19 Pandemic
We explore how AAT therapy can be self-administered safely by AATD patients, which is vital when their ability to travel is limited.
Caring for Patients With AATD in the Context of COVID-19
We explore AATD care in the context of Covid-19, including a hypothesis that AAT therapy could ameliorate COVID-19 symptoms.
Prioritizing Quality of Life When Caring for Patients With AATD
We discuss the importance of prioritizing quality of life parameters in AATD patient care, and how we can improve them.
Rare Care Podcast
Israeli biopharma giant Kamada is banking that its inhaled AAT therapy will “revolutionize” the treatment of alpha-1 antitrypsin deficiency (AATD).
Mark Brantly, MD, scientific director of the Alpha-1 Foundation, is the vice-chair of research in the Department of Medicine at the University of Florida in Gainesville, and has spent most of his career researching a cure for alpha-1 antitrypsin deficiency (AATD).
Alpha-1 Meeting Coverage
- Loading...
Loading...
Loading... 
Loading...